A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia

Priya, Lakshmi; Moorthy, Bini

doi:10.1155/2021/5557211

Cited by 3 publications

(4 citation statements)

References 6 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, when he was restarted on aripiprazole, after a month of paliperidone, her symptoms of hypersexuality relapsed. This finding is similar to the case reported by Priya et al, where a 24-year-old male with schizophrenia developed hypersexuality symptoms after initiation of aripiprazole, and cessation of the aripiprazole led to a reduction in hypersexual behaviors [2]. Therefore, due to the remission of symptoms after discontinuing aripiprazole and further relapse when it was restarted, the hypersexual symptoms are likely associated with aripiprazole use.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Aripiprazole Induced Hypersexuality in A 42-Year-Old Woman with Bipolar Disorder: A Rare Case Report

Olatunde,

Basiru,

Anombem

et al. 2023

JAMMR

View full text Add to dashboard Cite

Background: Aripiprazole use is associated with a very rare side effect of hypersexuality, which was experienced by the patient described in this case study. Hypersexuality can be a very distressing symptom and may also hinder medication compliance. Case Presentation: A 42-year-old woman with bipolar II disorder developed hypersexuality three weeks after starting aripiprazole, which was used in the treatment of her bipolar disorder. Discussion: Aripiprazole works by reducing dopaminergic neurotransmission in the mesolimbic pathway. It is believed that due to aripiprazole’s agonistic dopaminergic action in the mesolimbic circuit, it can increase sexual desire. Conclusion: This case report emphasizes the importance of closely monitoring patients taking aripiprazole for hypersexuality and adds to the existing body of knowledge of aripiprazole-induced hypersexuality.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Aripiprazole is an antipsychotic with partial agonistic activity at the dopaminergic D2 receptor [1,2]. The FDA approved it to treat schizophrenia and mood disorders in 2002 and 2006, respectively [3].…”

Section: Introductionmentioning

confidence: 99%

Aripiprazole Induced Hypersexuality in A 42-Year-Old Woman with Bipolar Disorder: A Rare Case Report

Olatunde,

Basiru,

Anombem

et al. 2023

JAMMR

View full text Add to dashboard Cite

show abstract

“…Considering the published case of ICS caused by aripiprazole and the time in which the ICS resolved [ 17 ], we looked at the published data on cariprazine metabolism. Cariprazine has a half-life of 2–4 days, and its metabolites desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR) have half-lives of 1–2 days and 1–3 weeks, respectively [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

“…In the recent pharmacovigilance–pharmacodynamic study Fusaroli and colleagues reported, that out of 19,887 reports of impulsivity, 5,898 reports are associated with antipsychotics and 3,100 with dopamine agonists [ 11 ]. In the literature review, hypersexuality was mostly reported in patients treated with aripiprazole [ 12 – 17 ], while there are some cases reporting hypersexuality on risperidone [ 18 ], olanzapine [ 19 ], and clozapine [ 20 ]. However, no reports have been published regarding ICS associated with the use of cariprazine.…”

Section: Introductionmentioning

confidence: 99%

Hypersexuality during treatment with cariprazine in a patient with schizophrenia? A case report

Prelog,

Palandacic

2023

BMC Psychiatry

View full text Add to dashboard Cite

Background Cariprazine is a third-generation antipsychotic with a unique mechanism of action. It functions as a partial agonist with high affinity for dopamine D2 and D3 and serotonin 5-HT1A receptors, an antagonist for 5-HT2A (moderate affinity) and 5-HT2B (high affinity) receptors. It binds to histamine H1 receptors and has a low affinity for 5-HT2C and alpha 1A-adrenergic receptors and no affinity for muscarinic (cholinergic) receptors. Among the troubling side effects, symptoms related to impulse control, such as hypersexuality, pathological gambling, compulsive shopping, compulsive eating etc., have been reported with the use of antipsychotic medications. However, no reports have been published regarding impulse control symptoms associated with cariprazine. We report a case of cariprazine-induced hypersexuality in a patient with schizophrenia, which was resolved by discontinuation of the medication. Case presentation A 67-year-old Caucasian woman with schizophrenia was admitted to the hospital inpatient unit after she discontinued olanzapine and psychotic symptoms reappeared. Prior to that, she was in remission, taking olanzapine for approximately one year. After discontinuation, she experienced auditory hallucinations with persecutory delusions and became anergic and withdrawn, with blunted affect. Olanzapine was reintroduced, as it was proven successful in her past treatments. However, since there were no changes, especially in negative symptoms, cariprazine was added. Seven days after the introduction of cariprazine, the patient developed compulsive sexual behaviour. Therefore, cariprazine was discontinued, and the hypersexual behaviour was resolved. Conclusions In this case report, we describe hypersexual behaviour that could potentially be induced by cariprazine. As a single case study, conclusions cannot be drawn. Controlled studies are warranted to better determine causality and the significance of this possible side-effect of cariprazine.

show abstract

Aripiprazole

2021

Reactions Weekly

View full text Add to dashboard Cite

A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia

Cited by 3 publications

References 6 publications

Aripiprazole Induced Hypersexuality in A 42-Year-Old Woman with Bipolar Disorder: A Rare Case Report

Aripiprazole Induced Hypersexuality in A 42-Year-Old Woman with Bipolar Disorder: A Rare Case Report

Hypersexuality during treatment with cariprazine in a patient with schizophrenia? A case report

Aripiprazole

Contact Info

Product

Resources

About